Skip To Main Content

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content

TANDEM Meeting 2026

The congress connection: CGvHD and Transplant Key Takeaways in 2026

IL-4, IL-13, AND IL-5 ARE DRIVERS OF SYSTEMIC TYPE 2 INFLAMMATION

Eosinophilic inflammation has multiple drivers1,2

The pathophysiology of ITP stems from complex immune dysregulation drives thrombocytopenia and inflammation

Rilzabrutinib a BTK inhibitor

Complex immune dysregulation impact on QoL

Interplay between the innate and adaptive immunity

Charting New Course: The Frontier of Early Intervention and Disease Modification in AD

Early Intervention and Disease Modification in Atopic Dermatitis

Prevalence of Type 1 Diabetes and Daily Life Impact

Expert thoughts on the rising prevalence of Type 1 Diabetes and its implications for public health. Type 1 diabetes represents few diabetes cases globally, creating both physical and psychological challenges.

Stages of Type 1 Diabetes and DKA Impact

Type 1 diabetes progresses from presymptomatic autoimmunity to symptomatic hyperglycemia, ultimately requiring lifelong insulin therapy. DKA can cause severe metabolic imbalances requiring hospitalization, significantly disrupting daily life and posing serious health risks.

Recommendation for Screening

Screening for individuals with first-degree relatives with T1D, particularly those with high-risk and Regular monitoring of autoantibodies and glucose tolerance can facilitate earlier diagnosis and treatment initiation.

Early Detection and Intervention

Early identification of autoantibodies can help predict T1D development before symptoms appear.